A pharmaceutical product can be technically sound and commercially promising, but that does not automatically make it ready for registration. Before a dossier reaches a regulatory authority, manufacturers need to confirm that the product, supporting evidence, manufacturing systems, and documentation all meet the requirements of the intended market.
This is where a regulatory gap assessment becomes an important part of the preparation process. Rather than waiting for regulators to identify missing information, manufacturers can review the submission in advance and address potential gaps before they affect the registration timeline.
So, what should manufacturers actually check?
1. Check the Requirements of the Target Market
The first step is to confirm that the regulatory strategy matches the country where the product will be registered. Requirements can differ significantly between markets, including documentation, application formats, supporting evidence, labeling, certificates, and registration pathways.
Manufacturers should identify the applicable regulatory authority, product category, submission route, technical requirements, and administrative requirements.
This is particularly important when using an existing dossier prepared for another country. A submission that worked in one market may require additional information or modification before it can be accepted elsewhere.
2. Confirm the Product Classification
Manufacturers should also verify that the product has been classified correctly before preparing the final registration package.
The classification can influence the regulatory pathway and the type of evidence required. Factors such as the active ingredient, dosage form, route of administration, intended indication, strength, and product composition may all be relevant.
A regulatory gap assessment should therefore confirm that the proposed registration pathway is appropriate for the specific product and its intended use.
3. Review the CMC and Quality Documentation
The Chemistry, Manufacturing and Controls (CMC) section requires particularly close attention. Manufacturers should check that the information provided about the product and its manufacturing process is complete, current, and internally consistent.
This review should cover:
- Active pharmaceutical ingredients and excipients
- Formulation and manufacturing process
- Finished product specifications
- Raw material specifications
- Analytical methods and validation
- Process validation
- Batch manufacturing information
- Packaging materials
- Quality control procedures
Manufacturers should also compare the technical documents against actual production practices. The registration dossier needs to accurately represent how the product is manufactured and controlled.
4. Check Stability Data and Shelf Life
Stability information is another important checkpoint before product registration. Manufacturers should verify that the available stability data supports the proposed shelf life, storage conditions, and packaging configuration.
The assessment should consider the batches included in stability studies, testing intervals, storage conditions, packaging systems, and results obtained throughout the study period.
Any gap between the available stability evidence and the requirements of the target regulatory authority should be identified early. This gives the manufacturer time to generate additional data or adjust the registration strategy before submission.
5. Assess GMP and Manufacturing Site Readiness
A strong dossier cannot compensate for weaknesses in manufacturing controls. Manufacturers should assess the readiness of the production facility and quality management system as part of their regulatory compliance review.
Key areas include GMP procedures, equipment qualification, process validation, cleaning validation, deviation management, CAPA, change control, documentation practices, and personnel training.
The manufacturer should also check that the manufacturing site details stated in the dossier match the current operational setup. Changes to sites, processes, equipment, or responsibilities should be properly evaluated and reflected in the submission where required.
6. Review Safety and Efficacy Evidence
Manufacturers should confirm that the evidence supporting the product’s safety and efficacy is appropriate for the proposed registration pathway.
Depending on the product, this may involve reviewing clinical studies, non-clinical data, published literature, bioequivalence information, or other supporting evidence.
The proposed indication, dosage, patient population, and product claims should be consistent with the evidence available. If the registration application makes claims that extend beyond the supporting data, regulators may request clarification or additional evidence.
7. Check Labels, Packaging and Product Information
Labeling is another area where relatively small errors can create unnecessary regulatory questions.
Manufacturers should review the proposed labels, cartons, package inserts, patient information, and other required product information against the requirements of the target market.
Important details such as the product name, strength, dosage form, composition, storage conditions, expiry information, warnings, manufacturer details, and directions for use should be checked carefully.
Just as importantly, the information on the packaging should match the information presented elsewhere in the registration dossier.
8. Look for Inconsistencies Across the Dossier
One of the most valuable checks before submission is a detailed consistency review.
Manufacturers should compare key information across the quality, clinical, administrative, labeling, and manufacturing sections. Product names, strengths, batch sizes, manufacturing sites, specifications, shelf life, storage conditions, formulation details, and other critical information should remain consistent.
Even an apparently minor discrepancy can lead to regulatory questions and additional correspondence. A final cross-check can therefore save considerable time during the review process.
9. Verify Administrative Documents
Technical information is only part of registration readiness. Manufacturers should also confirm that all administrative documents are complete and valid.
Depending on the market, this may include manufacturing licenses, GMP certificates, certificates of pharmaceutical product, powers of attorney, free sale certificates, certificates of analysis, legalized documents, application forms, fees, and other supporting documentation.
Each document should be checked for the correct product name, manufacturer details, dates, signatures, certifications, and validity period.
10. Create a Gap Closure Plan
Identifying regulatory gaps is useful only when there is a clear plan to close them. Manufacturers should categorize findings according to their regulatory importance and establish responsibility for each corrective action.
High-priority gaps should be addressed before submission, while lower-risk administrative or formatting issues can be managed during final dossier preparation.
A structured regulatory gap assessment therefore gives manufacturers more than a checklist. It creates a practical roadmap for improving submission readiness.
Prepare Before the Dossier Reaches the Regulator
The best time to discover a registration gap is before the application is submitted. By reviewing market requirements, product classification, CMC documentation, stability data, GMP readiness, safety evidence, labeling, administrative documents, and dossier consistency, manufacturers can identify issues while there is still time to resolve them.
For companies preparing a new pharmaceutical product registration, a systematic regulatory gap assessment can strengthen the submission and help create a smoother path through regulatory review. Pharma Wizard can support manufacturers in evaluating regulatory requirements, identifying potential gaps, and preparing documentation for greater submission readiness.
